Table 3.
CYP1A2 activity in smokers, switchers to THS, and abstainers in PMI’s clinical studies (per protocol populations).
| Study | Baseline |
Day 5 |
Day 90 |
||||||
|---|---|---|---|---|---|---|---|---|---|
| THS | CC | SA | THS | CC | SA | THS | CC | SA | |
| Mean (95 % CI) | Mean (95 % CI) | Mean (95 % CI) | Mean (95 % CI) | Mean (95 % CI) | Mean (95 % CI) | Mean (95 % CI) | Mean (95 % CI) | Mean (95 % CI) | |
| 5-day Poland (30) | 112.4 (104.4, 120.4) | 110.3 (100.7, 119.8) | 113.1 (98.4, 127.9) | 91.7 (85.2, 98.2) | 123.0 (112.1, 134.0) | 94.5 (82.6, 106.3) | NA | NA | NA |
| 5-day Japan (29) | 81.3 (73.9, 88.8) | 78.2 (69.8, 86.6) | 77.6 (69.6, 85.6) | 56.6 (52.3, 60.8) | 76.5 (68.7, 84.3) | 52.3 (47.4, 57.1) | NA | NA | NA |
| 90-day Japan (31) | 76.0 (70.5, 81.4) | 73.3 (66.6, 80.0) | 78.5 (70.3, 86.7) | 58.0 (54.0, 62.0) | 79.8 (72.0, 87.7) | 58.5 (52.5, 64.4) | 57.6 (53.2, 62.0) | 84.0 (73.6, 94.4) | 64.0 (55.6, 72.4) |
| 90-day U.S. (32) | 123.6 (114.4, 132.8) | 127.2 (113.9, 140.4) | 121.7 (102.7, 140.6) | 82.0 (75.0, 89.0) | 127.9 (116.2, 139.6) | 80.4 (65.6, 95.3) | 78.9 (68.4, 89.4) | 103.4 (87.9, 118.9) | 99.9 (47.3, 118.9) |